News
(2)April 2026
Royalty Pharma (RPRX) Reports $2.2B Revenue, Executes $1.5B in New Deals
# 🧾 What This Document Is This is Royalty Pharma's **Annual Report to Shareholders (ARS)**. Think of it as the company's "year in review" magazine, packaged for investors. It’s not just a dry legal filing; it’s designed to tell the story of their past year, showcase their financial health, and expl
Royalty Pharma Sets June 4 Meeting to Vote on Directors and Pay
# 🧾 What This Document Is This is a **proxy statement** (DEF 14A) for Royalty Pharma's 2026 Annual General Meeting. Think of it as an information packet and voting guide for shareholders. It explains what will be voted on at the meeting, provides details about the company's leadership and pay, and
Peers in Biotechnology
Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Incyte Corporation